The drug industry has announced it wants Congress to reopen the original 340B law to give the Health Resources and Services Administration additional rule- making authority to regulate the program. … [Read more...]
Goodbye, 340B Mega-Reg. Hello, 340B Guidance
Welcome back, proposed rules on manufacturer sanctions and dispute resolutionNovember 14, 2014—The Health Resources and Services Administration said for the record this morning that, in 2015, it "plans to issue a proposed guidance for notice and comment that will address key policy issues raised by various stakeholders committed to the integrity of the 340B program." … [Read more...]
Congress Asked to Investigate Genentech’s Specialty-Drug Switch
10 major academic medical centers seek expedited reviewNovember 14, 2014—Ten of the nation's leading academic medical centers have asked Congress to investigate Genentech's decision to move the world’s three top-selling cancer drugs into the more expensive specialty distribution channel. … [Read more...]
HRSA Withdraws 340B Mega-Reg, Will Issue Guidance Instead
Publication expected early next yearNovember 13, 2014—The Health Resources and Services Administration is withdrawing its planned comprehensive 340B program regulation tomorrow morning and instead will issue guidance early next year revising policies for key program elements. … [Read more...]
MedPAC Briefed About 340B Paper Requested by Lawmakers
Commission will not vote on findings or make recommendations to CongressNovember 10, 2014—Medicare Payments Advisory Commission staff members briefed the panel last week about a commission paper on the 340B program requested by congressional Medicare oversight committees. … [Read more...]
In Elections’ Wake, New Senate Leadership and a New GAO Study on 340B
Report is due to be issued in mid-2015November 5, 2014—U.S. Senate committees with responsibility for the 340B drug discount program will have new leaders starting early next year following the GOP's strong showing in yesterday's midterm elections. … [Read more...]
OIG Assessing Risk of Medicaid MCO Rebates on 340B-Purchased Drugs
Also, study about 340B and Medicare Part B is still on trackNovember 4, 2014—The Department of Health and Human Services Office of Inspector General is assessing the risk of manufacturer discounts and rebates both being paid on 340B-purchased drugs dispensed to Medicaid managed care beneficiaries, the OIG said in its fiscal year 2015 work plan. … [Read more...]